Welcome to LookChem.com Sign In|Join Free

CAS

  • or

186046-99-1

Post Buying Request

186046-99-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

186046-99-1 Usage

Description

(N6-Boc-N9-adeninyl)acetic acid is a chemical compound that features a Boc-protected N6-adenine group connected to acetic acid via a chain of nine atoms. (N6-Boc-N9-adeninyl)acetic acid is utilized in the synthesis of nucleoside analogs and serves as a building block for nucleic acid modifications. The Boc group shields the N6-adenine moiety, enabling selective deprotection and functionalization at the N9 position. Given its capacity to mimic and alter nucleoside structures, it holds potential in drug development and medical research. However, it is essential to handle this chemical with caution and adhere to safety guidelines and regulations due to its reactivity and potential hazards.

Uses

Used in Pharmaceutical Industry:
(N6-Boc-N9-adeninyl)acetic acid is used as a synthetic intermediate for the development of nucleoside analogs, which are crucial in the treatment of various diseases, including cancer and viral infections. Its ability to mimic and modify nucleoside structures allows for the creation of novel therapeutic agents with improved efficacy and reduced side effects.
Used in Biotechnology Industry:
In the biotechnology sector, (N6-Boc-N9-adeninyl)acetic acid is employed as a building block for the modification of nucleic acids. This enables the development of innovative genetic therapies and the manipulation of genetic material for research and clinical applications.
Used in Chemical Research:
(N6-Boc-N9-adeninyl)acetic acid is utilized as a research tool in chemical laboratories to study the structure and function of nucleosides and their role in biological processes. Its unique properties allow scientists to gain insights into the mechanisms of nucleic acid interactions and the potential for designing new drugs and therapies.
Used in Drug Development:
(N6-Boc-N9-adeninyl)acetic acid is used as a key component in the design and synthesis of new drugs targeting various diseases. Its potential applications in drug development are vast, as it can be used to create molecules with specific biological activities, such as antiviral, anticancer, or anti-inflammatory properties.

Check Digit Verification of cas no

The CAS Registry Mumber 186046-99-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,6,0,4 and 6 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 186046-99:
(8*1)+(7*8)+(6*6)+(5*0)+(4*4)+(3*6)+(2*9)+(1*9)=161
161 % 10 = 1
So 186046-99-1 is a valid CAS Registry Number.

186046-99-1Relevant articles and documents

Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae

Hansen, Anna Mette,Bonke, Gitte,Hogendorf, Wouter Frederik Johan,Bj?rkling, Fredrik,Nielsen, John,Kongstad, Kenneth T.,Zabicka, Dorota,Tomczak, Magdalena,Urbas, Malgorzata,Nielsen, Peter E.,Franzyk, Henrik

, p. 134 - 145 (2019/02/26)

Recent discovery of potent antibacterial antisense PNA-peptide conjugates encouraged development of a fast and efficient synthesis protocol that facilitates structure-activity studies. The use of an Fmoc/Boc protection scheme for both PNA monomers and amino acid building blocks in combination with microwave-assisted solid-phase synthesis proved to be a convenient procedure for continuous assembly of antisense PNA-peptide conjugates. A validated antisense PNA oligomer (CTCATACTCT; targeting mRNA of the acpP gene) was linked to N-terminally modified drosocin (i.e., RXR-PRPYSPRPTSHPRPIRV; X = aminohexanoic acid) or to a truncated Pip1 peptide (i.e., RXRRXR-IKILFQNRRMKWKK; X = aminohexanoic acid), and determination of the antibacterial effects of the resulting conjugates allowed assessment of the influence of different linkers as well as differences between the L- and D-forms of the peptides. The drosocin-derived compound without a linker moiety exhibited highest antibacterial activity against both wild-type Escherichia coli and Klebsiella pneumoniae (MICs in the range 2–4 μg/mL ~ 0.3–0.7 μM), while analogues displaying an ethylene glycol (eg1) moiety or a polar maleimide linker also possessed activity toward wild-type K. pneumoniae (MICs of 4–8 μg/mL ~ 0.6–1.3 μM). Against two colistin-resistant E. coli strains the linker-deficient compound proved most potent (with MICs in the range 2–4 μg/mL ~ 0.3–0.7 μM). The truncated all-L Pip1 peptide had moderate inherent activity against E. coli, and this was unaltered or reduced upon conjugation to the antisense PNA oligomer. By contrast, this peptide was 8-fold less potent against K. pneumoniae, but in this case some PNA-peptide conjugates exhibited potent antisense activity (MICs of 2–8 μg/mL ~ 0.3–1.2 μM). Most interestingly, the antibacterial activity of the D-form peptide itself was 2- to 16-fold higher than that of the L-form, even for the colistin- and tigecycline-resistant E. coli strains (MIC of 1–2 μg/mL ~ 0.25–0.5 μM). Low activity was found for conjugates with a two-mismatch PNA sequence corroborating an antisense mode of action. Conjugates containing a D-form peptide were also significantly less active. In conclusion, we have designed and synthesized antisense PNA-drosocin conjugates with potent antibacterial activity against colistin- and tigecycline-resistant E. coli and K. pneumonia without concomitant hemolytic properties. In addition, a truncated D-form of Pip1 was identified as a peptide exhibiting potent activity against both wild-type and multidrug-resistant E. coli, P. aeruginosa, and A. baumannii (MICs within the range 1–4 μg/mL ~ 0.25–1 μM) as well as toward wild-type Staphylococcus aureus (MIC of 2–4 μg/mL ~ 0.5–1.0 μM).

Expanding the scope of PNA-encoded libraries: divergent synthesis of libraries targeting cysteine, serine and metallo-proteases as well as tyrosine phosphatases

Debaene, Fran?ois,Da Silva, Julien A.,Pianowski, Zbigniew,Duran, Fernando J.,Winssinger, Nicolas

, p. 6577 - 6586 (2008/02/05)

Seven PNA-encoded combinatorial libraries targeting proteases and phosphatases with covalent reversible and irreversible mechanism-based inhibitors were prepared. The libraries were synthesized using modified PNA monomers, which dramatically increase the water solubility of the libraries in biologically relevant buffers. The libraries were shown to selectively inhibit targeted enzymes.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 186046-99-1